KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Current Deferred Revenue (2016 - 2017)

Historic Current Deferred Revenue for Pacira BioSciences (PCRX) over the last 8 years, with Q4 2017 value amounting to $102000.0.

  • Pacira BioSciences' Current Deferred Revenue fell 8285.71% to $102000.0 in Q4 2017 from the same period last year, while for Dec 2017 it was $102000.0, marking a year-over-year decrease of 8285.71%. This contributed to the annual value of $102000.0 for FY2017, which is 8285.71% down from last year.
  • Pacira BioSciences' Current Deferred Revenue amounted to $102000.0 in Q4 2017, which was down 8285.71% from $520000.0 recorded in Q1 2017.
  • Pacira BioSciences' Current Deferred Revenue's 5-year high stood at $1.4 million during Q2 2014, with a 5-year trough of $102000.0 in Q4 2017.
  • Its 5-year average for Current Deferred Revenue is $1.1 million, with a median of $1.0 million in 2013.
  • Per our database at Business Quant, Pacira BioSciences' Current Deferred Revenue crashed by 8655.79% in 2013 and then surged by 4670.78% in 2014.
  • Quarter analysis of 5 years shows Pacira BioSciences' Current Deferred Revenue stood at $1.0 million in 2013, then skyrocketed by 41.47% to $1.4 million in 2014, then changed by 0.0% to $1.4 million in 2015, then tumbled by 58.27% to $595000.0 in 2016, then tumbled by 82.86% to $102000.0 in 2017.
  • Its Current Deferred Revenue stands at $102000.0 for Q4 2017, versus $520000.0 for Q1 2017 and $595000.0 for Q4 2016.